From NAFLD to NASH to cirrhosis-new insights into disease mechanisms

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 11, 2013, Pages 627-636

  Wree, Alexander ^a   Broderick, Lori ^a   Canbay, Ali ^b   Hoffman, Hal M ^a   Feldstein, Ariel E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSE; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LINOLEIC ACID; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ALCOHOLIC STEATOHEPATITIS; APOPTOSIS; AUTOPHAGY; CARBOHYDRATE DIET; CELL DEATH; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FATTY LIVER; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIPID DIET; LIVER CELL DAMAGE; LIVER CIRRHOSIS; NATURAL KILLER T CELL; NECROPTOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PYROPTOSIS; REVIEW; RISK FACTOR;

DIET; DISEASE PROGRESSION; ENVIRONMENT; FATTY LIVER; GENETICS; HUMANS; IMMUNE SYSTEM; INDIVIDUALIZED MEDICINE; PREVALENCE; WORLD HEALTH;

EID: 84887319657     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.149     Document Type: Review

References (117)

1. Levene, A. P. & Goldin, R. D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152 (2012).
2. Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274-285 (2011).
3. Brunt, E. M., Neuschwander-Tetri, B. A., Oliver, D., Wehmeier, K. R. & Bacon, B. R. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 35, 1070-1082 (2004).
4. Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113-121 (2005).
5. Matteoni, C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419 (1999).
6. Ertle, J. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128, 2436-2443 (2011).
7. Lazo, M. & Clark, J. M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28, 339-350 (2008).
8. Mahady, S. E. & George, J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin. Liver Dis. 16, 631-645 (2012).
9. Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 (2010).
10. Bechmann, L. P. et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 56, 952-964 (2012).
11. Wree, A., Kahraman, A., Gerken, G. & Canbay, A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 83, 124-133 (2011).
12. Das, U. N. Biological significance of essential fatty acids. J. Assoc. Physicians India 54, 309-319 (2006).
13. Calder, P. C. n?3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83, 1505S-1519S (2006).
14. Seki, H., Tani, Y. & Arita, M. Omega?3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 89, 126-130 (2009).
15. Dentin, R. et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J. Clin. Invest. 115, 2843-2854 (2005).
16. Sekiya, M. et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP?1 suppression. Hepatology 38, 1529-1539 (2003).
17. Cortez-Pinto, H. et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin. Nutr. 25, 816-823 (2006).
18. Toshimitsu, K. et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23, 46-52 (2007).
19. Parker, H. M. et al. Omega?3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 56, 944-951 (2012).
20. Araya, J. et al. Increase in long-chain polyunsaturated fatty acid n?6/n?3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. 106, 635-643 (2004).
21. Puri, P. et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081-1090 (2007).
22. Hibbeln, J. R., Nieminen, L. R., Blasbalg, T. L., Riggs, J. A. & Lands, W. E. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am. J. Clin. Nutr. 83, 1483S-1493S (2006).
23. Feldstein, A. E. et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51, 3046-3054 (2010).
24. Zein, C. O. et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 56, 1291-1299 (2012).
25. Lazic, M. et al. Reduced dietary omega?6:omega?3 ration and 12/15-lipoxygenase defiency protect from high fat diet-induced steatohepatitis. J. Hepatol. 58, S409-S566 (2013).
26. Bohm, T. et al. Food-derived peroxidized fatty acids may trigger hepatic inflammation: a novel hypothesis to explain steatohepatitis. J. Hepatol. http://doi.dx.org/10.1016/j.hep.2013.04.025.
27. Ramsden, C. E. et al. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot. Essent. Fatty Acids 87, 135-141 (2012).
28. Neuschwander-Tetri, B. A. Carbohydrate intake and nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 16, 446-452 (2013).
29. Tappy, L. & Le, K. A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 90, 23-46 (2010).
30. Silbernagel, G. et al. Effects of 4?week very?high?fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br. J. Nutr. 106, 79-86 (2011).
31. Sobrecases, H. et al. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab. 36, 244-246 (2010).
32. Le, K. A. et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am. J. Clin. Nutr. 89, 1760-1765 (2009).
33. Maersk, M. et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6?mo randomized intervention study. Am. J. Clin. Nutr. 95, 283-289 (2012).
34. Feldstein, A. E. et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39, 978-983 (2003).
35. Chong, M. F., Fielding, B. A. & Frayn, K. N. Mechanisms for the acute effect of fructose on postprandial lipemia. Am. J. Clin. Nutr. 85, 1511-1520 (2007).
36. Abid, A. et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J. Hepatol. 51, 918-924 (2009).
37. Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961-1971 (2010).
38. Tappy, L. & Le, K. A. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clin. Res. Hepatol. Gastroenterol. 36, 554-560 (2012).
39. Vos, M. B. & Lavine, J. E. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57, 2525-2531 (2013).
40. Chalasani, N. et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139, 1567-1576 (2010).
41. Parks, B. W. et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 17, 141-152 (2013).
42. Dumas, M. E. et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA 103, 12511-12516 (2006).
43. Santoro, N. et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52, 1281-1290 (2010).
44. Santoro, N. et al. Predicting metabolic syndrome in obese children and adolescents: look, measure and ask. Obes. Facts 6, 48-56 (2013).
45. Netea, M. G. & van der Meer, J. W. Immunodeficiency and genetic defects of pattern-recognition receptors. N. Engl. J. Med. 364, 60-70 (2011).
46. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
47. Gao, B., Jeong, W. I. & Tian, Z. Liver: An organ with predominant innate immunity. Hepatology 47, 729-736 (2008).
48. Zarember, K. A. & Godowski, P. J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168, 554-561 (2002).
49. Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322-335 (2008).
50. Liu, S. et al. Role of toll-like receptors in changes in gene expression and NFB activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect. Immun. 70, 3433-3442 (2002).
51. Yang, L. & Seki, E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front. Physiol. 3, 138 (2012).
52. Mencin, A., Kluwe, J. & Schwabe, R. F. Toll-like receptors as targets in chronic liver diseases. Gut 58, 704-720 (2009).
53. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007).
54. Rivera, C. A. et al. Toll-like receptor?4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47, 571-579 (2007).
55. Hritz, I. et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 48, 1224-1231 (2008).
56. Ye, D. et al. Toll-like receptor'4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X?box binding protein?1 in mice. Gut 61, 1058-1067 (2012).
57. Watanabe, A. et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46, 1509-1518 (2007).
58. Gabele, E. et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Comm. 376, 271-276 (2008).
59. Petrasek, J., Dolganiuc, A., Csak, T., Kurt'Jones, E. A. & Szabo, G. Type I interferons protect from Toll-like receptor 9?associated liver injury and regulate IL?1 receptor antagonist in mice. Gastroenterology 140, 697-708 e4 (2011).
60. Himes, R. W. & Smith, C. W. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB 24, 731-739 (2010).
61. Miura, K. et al. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57, 577-589 (2013).
62. Rivera, C. A. et al. Toll-like receptor?2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol. 10, 52 (2010).
63. Fantuzzi, G. & Dinarello, C. A. Interleukin?18 and interleukin?1?: two cytokine substrates for ICE (caspase?1). J. Clin. Immunol. 19, 1-11 (1999).
64. Szabo, G. & Csak, T. Inflammasomes in liver diseases. J. Hepatol. 57, 642-654 (2012).
65. Wood, N. J. Microbiota: Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression. Nat. Rev. Gastroenterol. Hepatol. 9, 123 (2012).
66. Kamari, Y. et al. Lack of interleukin-1? or interleukin-1? inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J. Hepatol. 55, 1086-1094 (2011).
67. de Roos, B. et al. Attenuation of inflammation and cellular stress-related pathways maintains insulin sensitivity in obese type I interleukin?1 receptor knockout mice on a high-fat diet. Proteomics 9, 3244-3256 (2009).
68. Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E. & Nagy, L. E. Caspase?1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS ONE 8, e56100 (2013).
69. Pihlajamaki, J. et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J. Hepatol. 56, 663-670 (2012).
70. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408-415 (2011).
71. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
72. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).
73. Gao, B., Radaeva, S. & Park, O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leuko. Biol. 86, 513-528 (2009).
74. Kremer, M. et al. Kupffer cell and interleukin-12'dependent loss of natural killer T cells in hepatosteatosis. Hepatology 51, 130-141 (2010).
75. Tajiri, K., Shimizu, Y., Tsuneyama, K. & Sugiyama, T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 21, 673-680 (2009).
76. Adler, M. et al. Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J. Gastroenterol. 17, 1725-1731 (2011).
77. Syn, W. K. et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61, 1323-1329 (2012).
78. Locatelli, I., Sutti, S., Vacchiano, M., Bozzola, C. & Albano, E. NFB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT?cell?mediated responses. Clin. Sci. 124, 279-287 (2013).
79. Syn, W. K. et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51, 1998-2007 (2010).
80. Hua, J. et al. Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease. J. Lipid Res. 51, 1696-1703 (2010).
81. Miyagi, T. et al. Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. J. Gastroenterol. 45, 1247-1254 (2010).
82. Chekeni, F. B. et al. Pannexin 1 channels mediate find-me' signal release and membrane permeability during apoptosis. Nature 467, 863-867 (2010).
83. McClain, C. J., Barve, S. & Deaciuc, I. Good fat/bad fat. Hepatology 45, 1343-1346 (2007).
84. Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366-1374 (2007).
85. Nolan, C. J. & Larter, C. Z. Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it? J. Gastroenterol. Hepatol. 24, 703-706 (2009).
86. Li, Z. Z., Berk, M., McIntyre, T. M. & Feldstein, A. E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 284, 5637-5644 (2009).
87. Feldstein, A. E. et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-? expression via a lysosomal pathway. Hepatology 40, 185-194 (2004).
88. Feldstein, A. E., Werneburg, N. W., Li, Z., Bronk, S. F. & Gores, G. J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am. J. Physiol. 290, G1339-G1346 (2006).
89. Li, Z., Berk, M., McIntyre, T. M., Gores, G. J. & Feldstein, A. E. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 47, 1495-1503 (2008).
90. Barreyro, F. J. et al. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J. Biol. Chem. 282, 27141-27154 (2007).
91. Masuoka, H. C. et al. Mcl?1 degradation during hepatocyte lipoapoptosis. J. Biol. Chem. 284, 30039-30048 (2009).
92. Canbay, A., Friedman, S. & Gores, G. J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39, 273-278 (2004).
93. Canbay, A. et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 83, 655-663 (2003).
94. Canbay, A., Feldstein, A., Baskin-Bey, E., Bronk, S. F. & Gores, G. J. The caspase inhibitor IDN?6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 308, 1191-1196 (2004).
95. Canbay, A. et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J. Clin. Invest. 112, 152-159 (2003).
96. Canbay, A. et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123, 1323-1330 (2002).
97. Takehara, T. et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127, 1189-97 (2004).
98. Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
99. Crespo, J. et al. Gene expression of tumor necrosis factor - and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34, 1158-1163 (2001).
100. Gozuacik, D. & Kimchi, A. Autophagy and cell death. Curr. Top. Dev. Biol. 78, 217-245 (2007).
101. Singh, R. et al. Autophagy regulates lipid metabolism. Nature 458, 1131-1135 (2009).
102. Kim, I., Rodriguez-Enriquez, S. & Lemasters, J. J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 462, 245-253 (2007).
103. Caldwell, S. H. et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31, 430-434 (1999).
104. Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669 (2008).
105. Singh, R. et al. Autophagy regulates adipose mass and differentiation in mice. J. Clin. Invest. 119, 3329-3339 (2009).
106. Dunai, Z., Bauer, P. I. & Mihalik, R. Necroptosis: biochemical, physiological and pathological aspects. Pathol. Oncol. Res. 17, 791-800 (2011).
107. Roychowdhury, S., McMullen, M. R., Pisano, S. G., Liu, X. & Nagy, L. E. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 57, 1773-1783 (2013).
108. Jouan-Lanhouet, S. et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP?1 activation. Cell Death Differ. 19, 2003-2014 (2012).
109. Liedtke, C. et al. Loss of caspase?8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 141, 2176-2187 (2011).
110. Cookson, B. T. & Brennan, M. A. Pro-inflammatory programmed cell death. Trends Microbiol. 9, 113-114 (2001).
111. Dixon, L. J., Berk, M., Thapaliya, S., Papouchado, B. G. & Feldstein, A. E. Caspase?1?mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab. Invest. 92, 713-723 (2012).
112. Petrasek, J. et al. IL?1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Invest. 122, 3476-3489 (2012).
113. Bonar, S. L. et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PloS ONE 7, e35979 (2012).
114. Wree, A. et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis. Hepatology http://dx.doi.org/10. 1002/hep.26592.
115. Watanabe, A. et al. Inflammasome-mediated regulation of hepatic stellate cells. Am. J. Physiol. 296, G1248-G1257 (2009).
116. Malhi, H., Guicciardi, M. E. & Gores, G. J. Hepatocyte death: a clear and present danger. Physiol. Rev. 90, 1165-1194 (2010).
117. Csak, T. et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54, 133-144 (2011).